Transmitted HIV-1 resistance in patients without exposure to antiretroviral treatment. Guatemala
Abstract
The objective of this study was to describe the levels of transmitted HIV-1 resistance in patients with a recent
HIV diagnosis before starting ART, treated in Comprehensive Care Units in Guatemala during the years 2019 and 2020. The study included records of 185 HIV-positive adult patients, recently diagnosed with HIV without a history of ART use. The analysis was carried out in the DeepChek® v2.0 software, the Stanford HIVdb algorithm (v9.4 - 07/12/2022) was followed to classify resistance. 18.4% (95% CI 13.1 - 24.7%) of general resistance to some family of ARVs was found. There was evidence of 15.1% (95% CI 10.3 - 21.1%) of individual resistance to the NNRTI family, mainly affecting NVP and EFV; 2.2% (95% CI 0.6 - 5.4%) resistance to INTR, mostly to FTC/3TC; and 2.7% (95% CI 0.9 - 6.2%) of intermediate and low resistance IP NFV and LPV/r. Three cases presented multiple resistance to NRTIs + NNRTIs. The most frequently found mutations were K103N (41.2%), M184V/I (8.8%) and M46I (5.9%). The high transmitted resistance of HIV-1 in patients treated in different Comprehensive HIV Care Units demonstrates the importance of periodically analyzing the trend of resistance in people who have not been exposed to ARVs, which in turn is an indirect marker. of the presence of acquired resistance in the country, data that demonstrate the need for prompt and effective actions and interventions given its impact on public health.
Downloads
References
Palma V, Leiva I, Durán M, Ramos V, Sánchez C, Beltrán C, Ferrer P. Prevalencia de resistencia transmitida a drogas antirretrovirales en pacientes con infección por VIH en Chile (2014-2018). Revista médica de Chile. 2020;148(11):1550-1557.
Organización Mundial de la Salud (OMS). 2021. Farmacorresistencia del VIH. Disponible en: https://www.who.int/es/news-room/factsheets/detail/hiv-drug-resistance Consultado: diciembre 2022.
Ministerio de Salud Pública y Asistencia Social. Informe final: Encuesta de resistencia del VIH a los medicamentos antirretrovirales, Guatemala 2015-2016. Guatemala, 2017. Disponible en: https://www.sica.int/download/?111654 Consultado: febrero 2023.
Ministerio de Salud Pública y Asistencia Social. Guía de uso de los Antirretrovirales en personas con VIH y su aplicación profiláctica. Guatemala, 2019.
Avila-Ríos S, Mejía-Villatoro CR, García-Morales C, Soto-Nava M, Escobar I, Mendizabal R, et al. Prevalence and patterns of HIV transmitted drug resistance in Guatemala. Rev Panam Salud Publica. 2011;30(6):641-8.
Avila-Ríos S, García-Morales C, Garrido-Rodríguez D, Tapia-Trejo D, Girón-Callejas AC, Mendizábal-Burastero R, et al. HIV-1 drug resistance surveillance in antiretroviral treatment-naive individuals from a reference hospital in Guatemala, 2010-2013. AIDS Res Hum Retroviruses. 2015;31(4):401-11.
HIV Drug Resistance Database (HIVdb) Stanford University versión 9.4 (17/12/2022) disponible en: https://hivdb.stanford.edu/ Consultado: febrero 2023.
Wensing AM, Calvez V, Ceccherini-Silberstein F, Charpentier C, Günthard HF, Paredes R, Shafer RW, Richman DD. 2022 update of the drug resistance mutations in HIV-1. Top Antivir Med. 2022;30(4):559-574.
REGA HIV-1 Subtyping Tool - Version 3.0. Disponible en: http://dbpartners.stanford.edu:8080/RegaSubtyping/stanfordhiv/typingtool Consultado: julio 2023
Kral A, Wolff M, Villalobos H, Segovia C, Cortés CP. Evolución virológica de pacientes con infección por VIH que inician terapia antirretroviral con carga viral basal muy alta. Rev. chil. infectol. 2021;38(6):783-789.
Townsend D, Troya J, Maida I, Pérez-Saleme L, Satta G, Wilkin A, et al. First HAART in HIV-infected patients with high viral load: value of HIV RNA levels at 12 weeks to predict virologic outcome. J Int Assoc Physicians AIDS Care (Chic). 2009;8(5):314-7.
Avila-Rios S, Sued O, Rhee SY, Shafer RW, Reyes-Teran G, Ravasi G. Surveillance of HIV Transmitted Drug Resistance in Latin America and the Caribbean: A Systematic Review and Meta-Analysis. PLoS One. 2016;29;11(6):e0158560.
Girón-Callejas A, García-Morales C, Mendizabal-Burastero R, Román M, Tapia-Trejo D, Pérez-García M, et al. High levels of pretreatment and acquired HIV drug resistance in Nicaragua: results from the first nationally representative survey, 2016. J Int AIDS Soc. 2019;22(12):e25429.
Yabar CA, Vilcarino GF, Espetia S, Yaya MG, Salinas G, García-Fernández L, et al. Resistencia transmitida en VIH-1 de pacientes provenientes de nueve departamentos del Perú. Rev. perú. med. exp. salud pública. 2021;38(1):77-82.
Grupo de estudio del SIDA-SEIMIC (GeSIDA). Documento sobre la utilidad clínica de las resistencias antirretrovirales. 2018. Grupo de Educación en SIDA (GeSIDA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC). Julio 2018. Disponible en: https://gesida-seimc.org/wpcontent/uploads/2019/03/14_DOCUMENTO_SOBRE_UTILIDAD_CLINICA_RESISTENCIAS_A_ANTIRRETROVIRALES.pdf Consultado: 05 octubre 2023.
Sluis-Cremer N, Wainberg MA, Schinazi RF. Resistance to reverse transcriptase inhibitors used in the treatment and prevention of HIV-1 infection. Future Microbiol. 2015;10(11):1773-82.
Afani SA, Gallardo OAM. Resistencia a la terapia antiretroviral en la infección por virus de inmunodeficiencia humana. Rev. chil. infectol. 2011;28(5):461-469
Ministerio de Salud Pública y Asistencia Social. Departamento de Regulación de los Programas de Atención a las Personas. Programa Nacional de Prevención y Control de ITS, VIH y sida. Guía de Tratamiento Antirretroviral y de Infecciones Oportunistas en Guatemala, 2013. https://www.mcr-comisca.org/guatemala/767-guia-de-tratamientoantirretroviral-y-de-infecciones-oportunistas-en-guatemala-2013/file
Zapiola I, Cecchini D, Fernández GS, Martínez M, Rodríguez C, Bouzas MB. Resistencia de HIV-1 a drogas antirretrovirales en gestantes del área metropolitana de Buenos Aires. Medicina (B. Aires). 2016;76(6):349-354.
Ministerio de Salud Pública y Asistencia Social. Informe Nacional de la Cascada del Continuo de Atención en VIH. Guatemala, 2018.
Saura S, Jorquera V, Mascort C, Castellà I. Percepción del riesgo de infecciones de transmisión sexual/VIH en jóvenes desde una perspectiva de género (Gender meanings of the risk of sexually transmitted infections/HIVtransmission among young people). At Prim. 2020;52(3):218-219.
Copyright (c) 2024 Sabrina Navas, Cristina Quintana, Nydia Orózco, Aura Méndez, Claudia Medrano, Eduardo Celada, Johanna Samayoa
This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain their copyright and assign to the journal the right of first publication of their work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License. that allows sharing the work as long as the initial publication in this magazine is indicated.
